Tagged with ALS

Ichnos Cyril Konto, President & CEO of Ichnos Sciences comments on the company’s unique approach to finding new cancer treatments, the possibility of becoming fully independent from parent company Glenmark Pharmaceuticals and the licensing agreement Ichos has with Almirall for the IL-1RAP antagonist, ISB 880. … the Ichnos team has further…

Global With the rise of more transmissible variants and the reduced efficacy of outpatient monoclonal antibody therapies, the market for oral antivirals is expected to climb to new heights this year. Pfizer to take the lead, followed by Merck, and possibly, Shionogi. According to Airfinity’s recent COVID-19 treatment revenue forecast, the…

USA Ramona Sequeira, recently appointed chair of the PhRMA board of directors and president of Takeda’s US Business Unit and Global Portfolio Commercialization, gives her take on how the biopharma industry can do more to address the systemic inequities in US healthcare, including community-focused grant programs, clinical trial diversity initiatives, and…

Italy Ipsen’s Stephane Brocker discusses a transformational period for the iconic French mid-cap in recent years, how this has played out in Italy, and emergent trends – such as hybrid digital/in-person physician interactions – that have emerged from the COVID-19 pandemic period. Brocker also touches on Italy’s relevance to the global…

Italy Italy is a key destination for global clinical trial programs with EUR 700 million invested in 2020 alone according to national industry association Farmindustria, bringing access to medicines, knowledge, skills, and economic benefits. Here, Italy country managers from some of the world’s leading pharma companies weigh in on the pros…

Spain Soon after reaching its 60th anniversary, in 2015, the largest hospital in Catalonia and a group of sister institutions began working on the creation of a new type of campus. The idea was to follow the footsteps of world-leading healthcare hubs.   The idea of strengthening the cluster was an…

Global Writing in the February edition of DIA’s Global Forum magazine, Candice Del Rio of Curavit Clinical Research examines the applicability of decentralised clinical trials in oncology research, and their positive impact on both decreasing patient dropout rates and increasing patient engagement. Oncology represents the largest research area globally, with 6.5 percent…

USA Pfizer and MSD recently became the latest companies to have COVID-19 treatments authorised by either the US FDA or EMA. Their oral antiviral drugs joined several monoclonal antibodies and others on the list of options available to patients in Europe and the United States. Here is an updated list of…

Spain Sobi’s VP and general manager for Spain and Portugal, Pablo De Mora, comments on his experience during the pandemic, the Swedish company’s haematology and immunology portfolio, including its EMA-approved COVID-19 treatment, and the reimbursement challenges faced by rare disease players in Spain. Moreover, De Mora highlights Sobi’s vast clinical trials…

Spain Lilly’s Nabil Daoud highlights the evolution in the firm’s Spanish manufacturing and R&D footprint in recent years, discussed launch plans for its next-generation diabetes and obesity treatments, and outlines some of the key trends currently impacting healthcare in Spain.   Four years ago, a molecule discovered and designed by scientists…

Italy   In a wide-ranging and candid conversation, Amgen Italy General Manager Soren Giese outlines the strategy he put in place to restructure Amgen’s operations in the Italian market, the company’s third largest in Europe and sixth largest globally. Giese also touches on ensuring the affiliate’s product launch readiness, consistently increasing…

Italy Lilly’s president and general manager for its Italy hub, Huzur Devletsah, explains the company’s broad footprint in the country – where Lilly maintains a large manufacturing site that produces over half of their global insulin output and from which it oversees 28 countries. In addition, she comments on the upcoming…